多発性硬化症における組織適合性の決定因子,特に臨床経過を参考にする.

The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.

Tissue antigens·2011

Neonatal Immune Thrombocytopenia Due to Allo-or Autoantibodies: Clinical and Immunological Analysis of 83 Cases.

Platelets·2010

An update to HLA nomenclature, 2010.

Bone marrow transplantation·2010

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

European journal of neurology·2009

Gene expression analysis of interferon-beta treatment in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2008

Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.

Bone marrow transplantation·2008

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Case reports in dermatological medicine·2026

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Frontiers in endocrinology·2026

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Kidney diseases (Basel, Switzerland)·2026

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Cureus·2026

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Frontiers in lupus·2026

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

Frontiers in cell and developmental biology·2026

関連する実験動画

多発性硬化症における組織適合性の決定因子,特に臨床経過を参考にする

関連する概念動画

The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.

Neonatal Immune Thrombocytopenia Due to Allo-or Autoantibodies: Clinical and Immunological Analysis of 83 Cases.

An update to HLA nomenclature, 2010.

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

Gene expression analysis of interferon-beta treatment in multiple sclerosis.

Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

関連する実験動画

多発性硬化症における組織適合性の決定因子,特に臨床経過を参考にする

関連する概念動画

関連記事